Otsuka (OTCMKTS:OTSKY) Shares Gap Up – Still a Buy?

Shares of Otsuka Holdings Co., Ltd. – Unsponsored ADR (OTCMKTS:OTSKY) gapped up prior to trading on Thursday . The stock had previously closed at $32.94, but opened at $36.18. Otsuka shares last traded at $36.17, with a volume of 10,395 shares changing hands.

Wall Street Analysts Forecast Growth

Separately, Zacks Research upgraded shares of Otsuka from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 31st. One equities research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Otsuka currently has an average rating of “Hold”.

Otsuka Price Performance

The firm has a market capitalization of $38.80 billion and a price-to-earnings ratio of 15.24. The business’s 50-day moving average is $34.56 and its two-hundred day moving average is $32.77. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.67 and a current ratio of 2.17.

Otsuka (OTCMKTS:OTSKY) last issued its quarterly earnings data on Tuesday, April 28th. The company reported $0.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.43 by $0.16. Otsuka had a net margin of 15.01% and a return on equity of 12.33%. The firm had revenue of $3.96 billion during the quarter, compared to analysts’ expectations of $3.78 billion. Otsuka has set its FY 2026 guidance at 1.610-1.610 EPS. On average, equities analysts anticipate that Otsuka Holdings Co., Ltd. – Unsponsored ADR will post 1.98 earnings per share for the current year.

About Otsuka

Otsuka Pharmaceutical Co, Ltd., trading in the U.S. under the ticker OTCMKTS:OTSKY, is a global healthcare company headquartered in Tokyo, Japan. The firm’s core activities span the development, manufacturing and marketing of prescription pharmaceuticals, consumer healthcare products and nutraceuticals. Otsuka focuses its research on areas such as neuroscience, cardiovascular and renal therapies, and oncology, aiming to bring innovative treatments to patients worldwide.

Founded in 1964 by Busaburo Otsuka as a subsidiary of the Otsuka Group, the company has grown into a diversified healthcare enterprise over more than five decades.